MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-07-2023
Eargo General and Administrative Expenses 2011-2026 | EAR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.3 M | 49.9 M | 20.6 M | 12.5 M | 8.25 M | 5.77 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.3 M | 5.77 M | 25.2 M |
Quarterly General and Administrative Expenses Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.38 M | 9.45 M | 9.91 M | - | 11.7 M | 17.3 M | 14.9 M | - | 16.9 M | 8.43 M | 7.49 M | - | 5.16 M | 3.26 M | 6.08 M | - | 3.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.3 M | 3.26 M | 9.36 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K |  USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.22 | - | $ 121 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | USA |
 |
Globus Medical
GMED
|
1.18 B | $ 93.7 | 0.07 % | $ 12.7 B | USA |
 |
AdaptHealth Corp.
AHCO
|
382 M | $ 13.08 | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
LENSAR
LNSR
|
45.2 M | $ 5.21 | 2.36 % | $ 62.3 M | USA |
 |
Pulmonx Corporation
LUNG
|
101 M | $ 1.28 | - | $ 52.1 M | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
Orthofix Medical
OFIX
|
554 M | $ 12.32 | - | $ 488 M |  Curacao |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.61 | - | $ 38 M | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.21 | - | $ 317 M | USA |
 |
Sintx Technologies
SINT
|
6.2 M | $ 2.35 | - | $ 6.52 M | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
Electromed
ELMD
|
39.3 M | $ 26.0 | - | $ 220 M | USA |
 |
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | USA |
 |
Stryker Corporation
SYK
|
8.65 B | $ 329.01 | -0.03 % | $ 126 B | USA |
 |
Tactile Systems Technology
TCMD
|
88.7 M | $ 24.24 | -3.31 % | $ 554 M | USA |
 |
TELA Bio
TELA
|
15.7 M | $ 0.8 | - | $ 37.6 M | USA |
 |
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | USA |
 |
TransMedics Group
TMDX
|
185 M | $ 108.12 | - | $ 3.68 B | USA |
 |
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.12 | - | $ 1.29 M | USA |
 |
Tandem Diabetes Care
TNDM
|
445 M | $ 19.82 | - | $ 1.35 B | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Butterfly Network
BFLY
|
39.8 M | $ 5.48 | -0.09 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Varex Imaging Corporation
VREX
|
133 M | $ 12.71 | - | $ 526 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.82 | - | $ 371 M | USA |
 |
Delcath Systems
DCTH
|
43.5 M | $ 10.84 | - | $ 388 M | USA |
 |
Beyond Air
XAIR
|
26 M | $ 0.49 | - | $ 33.2 M | USA |
 |
LivaNova PLC
LIVN
|
549 M | $ 63.41 | - | $ 3.46 B |  Britain |
 |
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.08 | - | $ 18.3 M | USA |
 |
Xtant Medical Holdings
XTNT
|
29.4 M | $ 0.53 | - | $ 74 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.93 B | $ 92.59 | - | $ 18.8 B | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 37.87 | - | $ 1.18 B | USA |